Tag Archive for ‘clinical trials’
Gastric cancer is an aggressive malignancy with poor overall survival rates as a result, in part, of its predilection for peritoneal dissemination. Peritoneal metastasis (PM) is found in up to 55 to 60 percent of patients at the time of diagnosis by imaging or staging laparoscopy.1,2 In addition, despite multimodality therapy, peritoneal recurrence occurs in […]
Pancreatic cystic neoplasms occur in up to 20 percent of the U.S. adult population, and the incidence increases with more advanced age.1 In recent years, the prevalence of cystic neoplasms of the pancreas appears to be increasing as more patients undergo cross-sectional imaging in both the ambulatory and emergency setting. A recent study of patients […]
Ga-68 positron emission tomography has improved the clinical management of gastrointestinal and pancreatic neuroendocrine tumors, and multiple studies are ongoing to define its optimal role in clinical practice.
Balancing statistical relevance with clinician experience leads to innovative approaches to patient care.
The evolution of lung cancer surgery contributes to the sharpest drop in overall cancer mortality in the U.S.
This article describes the advancements in early detection and surgical treatment of lung cancer that led to improved lung cancer survival from a thoracic surgeon’s perspective.
The aim of the Alliance A191402CD trial is to evaluate the use of decision aids for men choosing treatment for located prostate cancer, particularly in minority populations.
A summary of the structure and function of the National Cancer Institute’s National Clinical Trial Network is provided.
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.
The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.
A summary of some of the research that evaluates the role of axillary reverse mapping in cancer patients.
Describes the traditional management of desmoid tumors as well as new approaches, including radiation therapy for locally aggressive tumors.
The ACS CRP will offer sessions at Clinical Congress 2019 on the topics of developing clinical trial and decreasing administrative burden associated with those trials.
Clinical trial data are examined to help develop a consensus approach for locally advanced gastric cancer.
Smoking cessation intervention trials examine potential outcome improvements for lung cancer patients.
Atezolizumab in the adjuvant treatment of stage III colon cancer: Can PD-L1 inhibition improve survival?
The study design for the ATOMIC trial (Alliance A021502), a randomized phase III study examining atezolizumab treatment of stage III colon cancer, is described.
Robotic surgery for hepatic neoplasms: Where does it fit in the minimally invasive surgery landscape?
This month’s column identifies prospective clinical trials aimed at clarifying the role of laparoscopic and robotic surgery for hepatic neoplasms.
Because many cases of ductal carcinoma in situ (DCIS) may remain stable without excision, more clinical trials are exploring the role of active surveillance in DCIS management.
The role of precision immunotherapy in treating solid tumors is summarized.
An educational program developed jointly by the ACS CRP and the Society of Surgical Oncology provides surgeons with the tools they need to actively participate in clinical trials
The role of immunotherapy in the treatment of urologic cancers is summarized and the efficacy of novel immunotherapeutics, particularly checkpoint inhibitors, are described, which may hold promise for a wide variety of tumor types.